Thomas A. Dineen
Affiliations: | 2005 | University of Michigan, Ann Arbor, Ann Arbor, MI |
Google:
"Thomas Dineen"Parents
Sign in to add mentor| William R. Roush | grad student | 2005 | University of Michigan | |
| (Studies on the intramolecular Diels -Alder reaction: Total synthesis of cochleamycin A and efforts toward the total synthesis of integramycin.) | ||||
| Andrew G. Myers | post-doc | 2005-2007 | Harvard | |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Eno MS, Brubaker JD, Campbell JE, et al. (2022) Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry |
| Graceffa RF, Boezio AA, Able J, et al. (2017) Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust In Vivo Activity. Journal of Medicinal Chemistry |
| Weiss MM, Dineen TA, Marx IE, et al. (2017) Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities. Journal of Medicinal Chemistry |
| Marx IE, Dineen TA, Able J, et al. (2016) Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement. Acs Medicinal Chemistry Letters. 7: 1062-1067 |
| Chen JJ, Liu Q, Yuan C, et al. (2015) Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious β-secretase inhibitors for the potential treatment of Alzheimer's disease. Bioorganic & Medicinal Chemistry Letters. 25: 767-74 |
| Epstein O, Bryan MC, Cheng AC, et al. (2014) Lead optimization and modulation of hERG activity in a series of aminooxazoline xanthene β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors. Journal of Medicinal Chemistry. 57: 9796-810 |
| Dineen TA, Chen K, Cheng AC, et al. (2014) Inhibitors of β-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-2'-amine (AMG-8718). Journal of Medicinal Chemistry. 57: 9811-31 |
| Huang H, La DS, Cheng AC, et al. (2012) Structure- and property-based design of aminooxazoline xanthenes as selective, orally efficacious, and CNS penetrable BACE inhibitors for the treatment of Alzheimer's disease. Journal of Medicinal Chemistry. 55: 9156-69 |
| Wood S, Wen PH, Zhang J, et al. (2012) Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived β-secretase inhibitors. The Journal of Pharmacology and Experimental Therapeutics. 343: 460-7 |
| Dineen TA, Weiss MM, Williamson T, et al. (2012) Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors. Journal of Medicinal Chemistry. 55: 9025-44 |